Autor: "Gonzalez, Pedro L." - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials.
Autorzy:: Riccobene T; AbbVie Inc., Madison, New Jersey, USA.
Lock J; AbbVie Inc., Madison, New Jersey, USA.
Lyles RD; AbbVie Inc., Madison, New Jersey, USA.
Georgiades B; AbbVie Inc., Madison, New Jersey, USA.
Nowak M; AbbVie Inc., Madison, New Jersey, USA.
Gonzalez PL; AbbVie Inc., Madison, New Jersey, USA.
Park J; AbbVie Inc., Madison, New Jersey, USA.
Rappo U; AbbVie Inc., Madison, New Jersey, USA.; Pokaż więcej
Źródło:: Open forum infectious diseases [Open Forum Infect Dis] 2023 May 09; Vol. 10 (6), pp. ofad256. Date of Electronic Publication: 2023 May 09 (Print Publication: 2023).
Typ publikacji:: Journal Article

Czasopismo naukowe

Skocz do pozycji: 2.

Tytuł:: Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials.
Autorzy:: Wilcox M; Department of Microbiology, Leeds Teaching Hospitals, University of Leeds, Leeds, LS1 3EX, UK. .
Yan JL; Pfizer, New York, NY, USA.
Gonzalez PL; AbbVie, Madison, NJ, USA.
Dryden M; Royal Hampshire County Hospital, Winchester, UK.
Stone GG; Pfizer, Groton, CT, USA.
Kantecki M; Pfizer, Paris, France.; Pokaż więcej
Źródło:: Infectious diseases and therapy [Infect Dis Ther] 2022 Feb; Vol. 11 (1), pp. 217-230. Date of Electronic Publication: 2021 Nov 06.
Typ publikacji:: Journal Article

Czasopismo naukowe

Skocz do pozycji: 3.

Tytuł:: Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
Autorzy:: Gonzalez PL; Infectious Disease Medical Affairs and Internal Medicine, AbbVie, Madison, NJ, USA. .; Becton-Dickinson, 1 Becton Dr, Franklin Lakes, NJ, 07417-1880, USA. .
Rappo U; Clinical Development, Infectious Diseases, AbbVie, Madison, NJ, USA.; BiomX Inc., Branford, CT, USA.
Akinapelli K; Medical Affairs Infectious Diseases, AbbVie, Madison, NJ, USA.; Iterum Therapeutics, Old Saybrook, CT, USA.
McGregor JS; Medical Affairs Infectious Diseases, AbbVie, Madison, NJ, USA.
Puttagunta S; Infectious Disease Medical Affairs and Internal Medicine, AbbVie, Madison, NJ, USA.; BiomX Inc., Branford, CT, USA.
Dunne MW; Infectious Disease Medical Affairs and Internal Medicine, AbbVie, Madison, NJ, USA.; Iterum Therapeutics, Old Saybrook, CT, USA.; Pokaż więcej
Źródło:: Infectious diseases and therapy [Infect Dis Ther] 2022 Feb; Vol. 11 (1), pp. 423-434. Date of Electronic Publication: 2021 Dec 14.
Typ publikacji:: Journal Article

Czasopismo naukowe

Skocz do pozycji: 4.

Tytuł:: Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials.
Autorzy:: Gonzalez PL; AbbVie, Madison, NJ, USA. .
Rappo U; AbbVie, Madison, NJ, USA.
Mas Casullo V; AbbVie, Madison, NJ, USA.
Akinapelli K; Independent Consultant, Hamden, CT, USA.
McGregor JS; AbbVie, Madison, NJ, USA.
Nelson J; AbbVie, Madison, NJ, USA.
Nowak M; AbbVie, Madison, NJ, USA.
Puttagunta S; Iterum Therapeutics, Old Saybrook, CT, USA.
Dunne MW; Iterum Therapeutics, Old Saybrook, CT, USA.; Pokaż więcej
Źródło:: Infectious diseases and therapy [Infect Dis Ther] 2021 Mar; Vol. 10 (1), pp. 471-481. Date of Electronic Publication: 2021 Jan 30.
Typ publikacji:: Journal Article

Czasopismo naukowe

Skocz do pozycji: 5.

Tytuł:: Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
Autorzy:: Rappo U; Clinical Development, Allergan plc, Madison, New Jersey.
Puttagunta S; Clinical Development, Allergan plc, Madison, New Jersey.
Shevchenko V; Orthopedic and Trauma Department, Cherkasy Regional Hospital, Cherkasy, Ukraine.
Shevchenko A; Orthopedic and Trauma Department, Cherkasy Regional Hospital, Cherkasy, Ukraine.
Jandourek A; Clinical Development, Allergan plc, Madison, New Jersey.
Gonzalez PL; Medical Affairs, Allergan plc, Jersey City, New Jersey.
Suen A; Clinical Development, Allergan plc, Madison, New Jersey.
Mas Casullo V; Clinical Development, Allergan plc, Madison, New Jersey.
Melnick D; Clinical Development, Allergan plc, Madison, New Jersey.
Miceli R; Clinical Development, Allergan plc, Madison, New Jersey.
Kovacevic M; Clinical Development, Allergan plc, Madison, New Jersey.
De Bock G; Clinical Development, Allergan plc, Madison, New Jersey.
Dunne MW; Clinical Development, Allergan plc, Madison, New Jersey.; Pokaż więcej
Źródło:: Open forum infectious diseases [Open Forum Infect Dis] 2018 Dec 10; Vol. 6 (1), pp. ofy331. Date of Electronic Publication: 2018 Dec 10 (Print Publication: 2019).
Typ publikacji:: Journal Article

Czasopismo naukowe

Informacja